New & Notable
Big Pharma's $13.8B DTC ad spend drives drug costs
A CSRxP report reveals Big Pharma spent $13.8B on direct-to-consumer advertising in 2023, prompting renewed calls to eliminate corporate tax deductions worth up to $1.7B annually.
Optimizing prior authorization with AI-driven efficiency
As prior authorization poses a hurdle in healthcare, AI-driven solutions are reshaping the process by reducing delays, improving efficiency and minimizing administrative burdens.
Medical device report delays raise safety concerns
A BMJ study finds nearly one-third of medical device makers submit adverse event reports late, with 54.8% linked to 3 manufacturers and 13 devices, raising safety concerns.
Exploring FDA-approved biosimilar insulin products
FDA-approved biosimilar insulin products, such as Semglee, Rezvoglar and Merilog, expand access and provide cost-effective alternatives to reference biologics.
Insights
Insights is research conducted by and for TechTarget Xtelligent Healthcare. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.
Access All Reports
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
AI prior authorization denials threaten patient care
AMA survey warns that 61% of physicians are alarmed by AI-driven prior authorization, with denials delaying care and contributing to serious patient harm.
-
FDA approves Merilog, first NovoLog biosimilar for diabetes
The FDA approved Merilog (insulin-aspart-szjj), the first biosimilar to NovoLog, enhancing insulin accessibility and competition while potentially lowering costs.
-
Emerging vision risks linked to semaglutide, tirzepatide
Recent data points to potential ophthalmic complications, including optic neuropathy and maculopathy, in patients treated with semaglutide and tirzepatide.
-
FDA approves Journavx, a safer painkiller alternative
The FDA's approval of Journavx, a first-in-class non-opioid analgesic for acute pain, marks a breakthrough that could reshape pain management and reduce reliance on opioids.
-
FDA expands Ozempic's use for kidney, heart protection
Novo Nordisk's Ozempic gains FDA approval for kidney and heart protection in type 2 diabetes patients with chronic kidney disease, reinforcing its role in cardiometabolic care.
-
Insulin prices fall amid growing competition, legislative action
Generics, biosimilars, pricing strategies and regulatory policies are driving a decline in insulin prices, creating affordability and improved access for patients.
Features
-
How AI is revolutionizing clinical trials, drug development
AI is transforming clinical trials by enhancing patient recruitment, site selection and data analysis. These advancements accelerate drug development while reducing costs.
-
How PBMs limit access to MS therapies
Pharmacy benefit managers inflate specialty generic prices, restrict pharmacy choice and increase patient costs, leaving many life-saving multiple sclerosis therapies inaccessible.
-
Understanding tirzepatide compounding restrictions
The FDA’s tirzepatide compounding rules present challenges for pharmacies, with deadlines in February and March of 2025, requiring compliance to avoid legal and regulatory risks.
-
Exploring FDA-approved anti-obesity medications
As obesity rates continue to rise, FDA-approved anti-obesity medications play a crucial role in weight management, complementing diet and exercise to support long-term health.